CHICAGO - Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a company focused on AI-driven precision cardiovascular medicine, has been granted a notice of allowance by the U.S. Patent and Trademark Office for a patent application related to cardiovascular disease (CVD) detection technology.
The patent, exclusively licensed from the University of Iowa Research Foundation, is the second U.S. patent in this family and complements existing patents in the European Union, China, India, and Australia.
This development comes as the American Heart Association reports that CVD is responsible for a death every 34 seconds in the United States. With heart disease being the leading cause of death in the country, the need for improved detection and management methods is critical, especially considering the high number of silent heart attacks that go undetected.
Cardio Diagnostics' IP portfolio includes their Integrated Epigenetic-Genetic Engine technology, which underpins their Epi+Gen CHD™ and PrecisionCHD™ clinical blood tests, as well as software solutions HeartRisk™ and CardioInnovate360™. These tools are designed to assist healthcare stakeholders in making informed decisions to address the human and financial toll of heart disease.
The company's CEO and Co-Founder, Meesha Dogan, Ph.D., emphasized the importance of the patent in protecting their advanced genomics and AI-powered technology, which aims to enhance risk assessment, diagnosis, treatment, and management of CVD.
Cardio Diagnostics' approach to cardiovascular disease prevention and management leverages their proprietary AI-driven technology to offer personalized solutions. The company's focus is on making these solutions more accessible while ensuring they are protected by a robust intellectual property strategy.
The recent patent issuance is part of the company's ongoing efforts to strengthen its IP portfolio and enhance its position in the field of cardiovascular medicine. This information is based on a press release statement from Cardio Diagnostics Holdings, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.